Genmab | GEN - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Almirall EUR 1.53B 43.26M 2026-06
Amarin USD 443.62M 5.8M 2026-06
Amgen USD 11.69B 2.5B 2026-06
argenx SE USD 8.42B 1.09B 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
Bayer EUR 29.71B 863M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Demant DKK 11.24B 1.4B 2026-06
Exelixis USD 1.84B 91.99M 2026-06
Fresenius Medical Care EUR 13.53B 673.44M 2026-06
Genmab DKK 5.96B 275M 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
GN Store Nord DKK 10.27B 146M 2026-06
GRIFOLS EUR 7.98B 2.52B 2026-06
Hikma Pharmaceutical USD 2.59B 42M 2025-12
Insmed USD 757.49M 52.64M 2026-06
Lakefront Biotherapeutics EUR 3.26B 10.26M 2026-06
Lonza CHF 9.13B 513M 2025-12
Merck EUR 30.17B 430M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sanofi EUR 69.57B 3.24B 2026-06
UCB EUR 10.87B 1.18B 2025-12